The survival of patients with the two most prevalent forms of systemic amyloidosis — light chain amyloidosis, which is caused by aggregates of monoclonal immunoglobulin light chains, and transthyretin amyloidosis (ATTR amyloidosis), which is caused by aggregates of wild-type or variant transthyretin — is determined largely by cardiac involvement. Therapy…
The New England Journal of Medicine: Search Results in Neurology/Neurosurgery
